INCRETIN-BASED THERAPY
-
- FUJITANI YOSHIO
- DEPARTMENT OF MEDICINE, METABOLISM AND ENDOCRINOLOGY, JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE
Bibliographic Information
- Other Title
-
- インクレチン療法
- インクレチン リョウホウ
Search this article
Description
The use of incretin-based therapies, such as DPP-4 inhibitors and GLP-1 receptor agonists, has increased dramatically due to their efficacy, low risk of hypoglycemia, and potential for preserving beta-cell function. Based on their effects on glycemic control and the likelihood of aiding in weight loss, GLP-1 receptor agonists provide a unique treatment option for people with type 2 diabetes. The potential benefit of incretin-based therapies in the treatment of type 2 diabetes patients and cardiovascular disease is currently an active area of research. While the potential benefits of incretin-based therapies in cardiovascular risk reduction are promising, results from ongoing outcomes-based studies will help determine the role of these agents in diabetes management.
Journal
-
- Juntendo Medical Journal
-
Juntendo Medical Journal 58 (6), 490-497, 2012
The Juntendo Medical Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205746604416
-
- NII Article ID
- 130004712288
- 40019548540
-
- NII Book ID
- AN00113194
-
- ISSN
- 21882134
- 00226769
-
- NDL BIB ID
- 024201255
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed